Clinical Course and CSF Amyloid β Protein Precursor Having the Site of Application of the Protease Inhibitor (APPI) Levels in Patients with Dementia of the Alzheimer Type (1993)

Letters| February 05 1993 Clinical Course and CSF Amyloid β Protein Precursor Having the Site of Application of the Protease Inhibitor (APPI) Levels in Patients with Dementia of the Alzheimer Type Subject Area: Geriatrics and Gerontology , Neurology and Neuroscience , Psychiatry and Psychology Katsuya Urakami; Katsuya Urakami a Division of Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Nishimachi, Yonago; Search for other works by this author on: This Site PubMed Google Scholar Kazuro Takahashi; Kazuro Takahashi a Division of Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Nishimachi, Yonago; Search for other works by this author on: This Site PubMed Google Scholar Akitsugu Okada; Akitsugu Okada a Division of Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Nishimachi, Yonago; Search for other works by this author on: This Site PubMed Google Scholar Takafumi Oshima; Takafumi Oshima a Division of Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Nishimachi, Yonago; Search for other works by this author on: This Site PubMed Google Scholar Yoshiki Adachi; Yoshiki Adachi a Division of Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Nishimachi, Yonago; Search for other works by this author on: This Site PubMed Google Scholar Shigenobu Nakamura; Shigenobu Nakamura b Third Department of Internal Medicine, Faculty of Medicine, Hiroshima University, Hiroshima; Search for other works by this author on: This Site PubMed Google Scholar Nobuya Kitaguchi; Nobuya Kitaguchi c Bio-Science Laboratory, Life Science Research Laboratories, Asahi Chemical Industry Co., Ltd, Shizuoka; Search for other works by this author on: This Site PubMed Google Scholar Yasuo Tokushima; Yasuo Tokushima c Bio-Science Laboratory, Life Science Research Laboratories, Asahi Chemical Industry Co., Ltd, Shizuoka; Search for other works by this author on: This Site PubMed Google Scholar Shuji Yamamoto; Shuji Yamamoto c Bio-Science Laboratory, Life Science Research Laboratories, Asahi Chemical Industry Co., Ltd, Shizuoka; Search for other works by this author on: This Site PubMed Google Scholar Seigo Tanaka Seigo Tanaka d Department of Neurology, Faculty of Medicine, Kyoto University, Kyoto, Japan Search for other works by this author on: This Site PubMed Google Scholar Dementia (1993) 4 (1): 59–60. https://doi.org/10.1159/000107297 Article history Published Online: February 05 1993 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Katsuya Urakami, Kazuro Takahashi, Akitsugu Okada, Takafumi Oshima, Yoshiki Adachi, Shigenobu Nakamura, Nobuya Kitaguchi, Yasuo Tokushima, Shuji Yamamoto, Seigo Tanaka; Clinical Course and CSF Amyloid β Protein Precursor Having the Site of Application of the Protease Inhibitor (APPI) Levels in Patients with Dementia of the Alzheimer Type. Dementia 1 January 1993; 4 (1): 59–60. https://doi.org/10.1159/000107297 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsDementia Search Advanced Search Article PDF first page preview Close Modal 1993Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.